OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc.
Your view on OKUR
Overview
What the company does, where it operates, and who runs it.
About OnKure Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Nicholas A. Saccomano
- Headquarters
- US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Nicholas A. Saccomano
- Headquarters
- US
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
Infographics
Visual summary of the business at a glance.
Media
Videos and interviews covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Comparables
List of peer companies in the same industry.
Institutional Ownership
Which funds and firms own the stock.
Insider Trading
Recent buying and selling by company executives.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
News
Latest headlines and market coverage.